Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.70 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.54 |
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | PAM | P19021 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3503231 | 1.00 | DGKA (0.70) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL3505591 | 1.00 | DGKA (0.70) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL820326 | 1.00 | DGKA (0.70) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL8847123 | 1.00 | DGKA (0.70) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL19709434 | 1.00 | DGKA (0.70) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL3503023 | 1.00 | DGKA (0.70) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL29288177 | 1.00 | DGKA (0.70) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL1683937 | 1.00 | DGKA (0.70) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL12742199 | 0.98 | DGKA (0.68) | DGKADNM1PRSS1PRSS2PRSS3 | |
| SCHEMBL12742182 | 0.98 | DGKA (0.68) | DGKADNM1PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
| US-6737544-B1 | HEATING ABOVE MELTING POINT | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-18 | — | — | US | disclosed |
| US-6639070-B1 | 4-substituted 1,3,4-oxadiazines; herbicides | BASF AKTIENGESELLSCHAFT (DE) | 2003-10-28 | — | — | US | disclosed |
| EP-1187819-B1 | N-SUBSTITUTED PERHYDRO DIAZINE | BASF AG (DE) | 2003-07-23 | — | — | EP | disclosed |
| EP-1315733-A2 | METHOD FOR PRODUCING ANELLATED TETRAHYDRO-[1H]-TRIAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2003-06-04 | — | — | EP | disclosed |
| EP-1052901-B1 | STORAGE STABLE AQUEOUS FORMULATIONS BASED ON N-PHENYL-3,4,5,6-TETRAHYDROPHTHALIMIDE HERBICIDES | BASF AG (DE) | 2002-09-04 | — | — | EP | disclosed |
| EP-0891336-B1 | SUBSTITUTED 1-METHYL-3-BENZYLURACILS | BASF AG (DE) | 2002-06-05 | — | — | EP | disclosed |
| EP-1187820-A1 | SUBSTITUTED UREAS | BASF AKTIENGESELLSCHAFT (DE) | 2002-03-20 | — | — | EP | disclosed |
| WO-2002020531-A2 | METHOD FOR PRODUCING ANELLATED TETRAHYDRO-[1H]-TRIAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2002-03-14 | — | — | WO | disclosed |
| US-6313070-B1 | MIXTURE OF ANIONIC AND NONIONIC SURFACTANTS, THIXOTROPIC ADDITIVE, WATER, OTHER HERBICIDES, OTHER AUXILIARIES | BASF AKTIENGESELLSCHAFT (DE) | 2001-11-06 | — | — | US | disclosed |
| EP-0835248-B1 | 1-AMINO-3-BENZYLURACILS | BASF AG (DE) | 2001-02-21 | — | — | EP | disclosed |
| WO-2001000602-A1 | SUBSTITUTED UREAS | BASF AKTIENGESELLSCHAFT (DE) | 2001-01-04 | — | — | WO | disclosed |
| US-6150303-A | Substituted 3-phenylisoxazolines | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-21 | — | — | US | disclosed |
| EP-0891336-A1 | SUBSTITUTED 1-METHYL-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1999-01-20 | — | — | EP | disclosed |
| EP-0835248-A1 | 1-AMINO-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1998-04-15 | — | — | EP | disclosed |
| WO-1997035845-A1 | SUBSTITUTED 1-METHYL-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1997-10-02 | — | — | WO | disclosed |
| WO-1997001543-A1 | 1-AMINO-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1997-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | CBR1, CBR3, QSOX1 | DGKA 3924/4885DNM1 1396/4885PRSS1 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.